Answers are grounded in this paper and cite their sources.
Background: Albuminuria, the conventional marker of diabetic nephropathy (DN), is neither sensitive nor specific for early glomerular injury. Podocalyxin is the major sialoglycoprotein of the podocyte surface and is shed into urine when podocytes are injured. Aim: To estimate urinary podocalyxin in patients with type 2 diabetic nephropathy, compare it with controls, and correlate it with conventional renal and glycaemic parameters. Materials and Methods: This hospital-based case–control study included 50 patients with type 2 diabetic nephropathy and 50 controls. Urinary podocalyxin was measured by sandwich ELISA. Blood urea, serum creatinine, fasting and postprandial plasma glucose, urine protein–creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) were determined. Groups were compared with the unpaired t test and associations were tested with Pearson’s correlation. Results: Mean urinary podocalyxin was 180.4 ± 56.9 ng/ml in cases and 29.9 ± 6.7 ng/ml in controls (p < 0.0001), with no overlap between the groups. Among cases, podocalyxin correlated positively with duration of diabetes (r = 0.863, p < 0.0001) and UPCR (r = 0.727, p < 0.0001), and negatively with eGFR (r = ?0.547, p < 0.0001). It did not correlate with age, body mass index, blood urea or serum creatinine. Mean podocalyxin rose from 99.9 ng/ml in patients with diabetes for less than 10 years to 224.9 ng/ml in those with more than 15 years. Conclusion: Urinary podocalyxin is markedly raised in type 2 diabetic nephropathy and tracks duration of diabetes, proteinuria and declining eGFR more closely than urea or creatinine do. It is a promising non-invasive marker of podocyte injury; its value in the pre-albuminuric stage needs confirmation in normoalbuminuric cohorts.
No takes yet. Share an insight, caveat, or question.
Chandran et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: